Voriconazole associated mucormycosis in a patient with relapsed acute lymphoblastic leukemia and hematopoietic stem cell transplant failure: A case report

Sharifpour, Ali; Gholinejad-Ghadi, Nahid; Ghasemian, Roya; Seifi, Zahra; Âghili, Seyed Reza; Zaboli, Ehsan; Abdi, R.; Shokohi, Tahereh

doi:10.1016/j.mycmed.2018.05.008

Cited by 5 publications

(2 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The awareness of this entity for clinical professionals is critical in patient management. It is vital to have strong index of suspicion for mucormycosis for proper diagnosis and accurate laboratory diagnostic approaches using molecular and conventional techniques are the needful methods for managing this catastrophic infection (Sharifpour et al 2018 ).…”

Section: Risk Factors Causing Mucormycosismentioning

confidence: 99%

Focusing COVID-19-associated mucormycosis: a major threat to immunocompromised COVID-19

Sharma

Wani

Behl

et al. 2022

Environ Sci Pollut Res

View full text Add to dashboard Cite

COVID-19 disease has been identified to cause remarkable increase of mucormycosis infection cases in India, with the majority of cases being observed in individuals recovering from COVID-19. Mucormycosis has emanated as an outcome of the recent COVID-19 pandemic outbreak as rapidly developing fatal illness which was acquired by Mucorales fungus which is a subcategory of molds known as mucormycetes. Mucormycosis is one of the serious, sporadic mycotic illnesses which is a great threat to immunocompromised COVID-19 patients and affects people of all ages, including children with COVID-19 infections. This is associated with tissue damaging property and, therefore, causes serious clinical complications and elevated death rate. The COVID-19-associated mucormycosis or “black fungus” are the terms used interchangeably. The rapid growth of tissue necrosis presenting as “rhino-orbital-cerebral, pulmonary, cutaneous, gastrointestinal, and disseminated disease” are various clinical forms of mucormycosis. The patient’s prognosis and survival can be improved with proper surgeries using an endoscopic approach for local tissue protection in conjunction with course of appropriate conventional antifungal drug like Amphotericin-B and novel drugs like Rezafungin, encochleated Amphotericin B, Orolofim, and SCY-078 which have been explored in last few years. This review provides an overview of mucormycosis including its epidemiology, pathophysiology, risk factors, its clinical forms, and therapeutic approaches for disease management like antifungal therapy, surgical debridement, and iron chelators. The published patents and ongoing clinical trials related to mucormycosis have also been mentioned in this review. Graphical abstract

show abstract

Section: Risk Factors Causing Mucormycosismentioning

confidence: 99%

Focusing COVID-19-associated mucormycosis: a major threat to immunocompromised COVID-19

Sharma

Wani

Behl

et al. 2022

Environ Sci Pollut Res

View full text Add to dashboard Cite

show abstract

“…[2][3][4][5][6] It usually affects patients with poorly controlled diabetes and individuals with immunosuppression. [7][8][9][10][11] Frequent clinical presentations include rhino-cerebral, pulmonary, and cutaneous forms, and less frequently, gastrointestinal, disseminated, and miscellaneous forms. [12][13][14][15][16] This case report will focus on cutaneous mucormycosis.…”

Section: Introductionmentioning

confidence: 99%

Cutaneous Mucormycosis of the Interscapular Region in an Immunocompetent Patient

Doshi

Sanghvi

Doctor

et al. 2021

EMJ Microbiol Infect Dis

View full text Add to dashboard Cite

Mucormycosis is an invasive fungal infection caused by opportunistic fungi of the phylum Glomeromycotan, subphylum Mucormycotina, mainly affecting individuals with immunosuppression. Cutaneous mucormycosis is the third most common clinical form of the disease preceded by pulmonary and rhinocerebral mucormycosis. The usual factors predisposing to this infection are individuals who are immunocompromised with conditions like HIV, haematological malignancies, and diabetes mellitus, but a significant proportion of patients are immunocompetent. The agents of mucormycosis are abundantly present in nature and are transmitted to the skin by direct inoculation. It may be due to needle sticks, stings, and bites by animals, motor-vehicle accidents, natural disasters, and burn injuries. The clinical presentation is non-specific, but an indurated plaque that rapidly evolves to necrosis (eschar) is a common finding. The infection can invade locally, and also penetrate into the adjacent fat, muscle, fascia, and bone, or become disseminated. It is difficult to diagnose because of the non-specific presentation of mucormycosis. Biopsy and culture should be performed. Treatment consists of multidisciplinary management, including surgical debridement, use of antifungal drugs (amphotericin B and posaconazole), and reversal of underlying risk factors, when possible. Mortality rates are significant, ranging from 4% to 10% in localised mucormycosis infection, but are lower than the other forms of the disease. The authors present a case here of a 38-year-old immunocompetent male with cutaneous mucormycosis at the interscapular region.

show abstract

Voriconazole

2018

Reactions Weekly

View full text Add to dashboard Cite

Voriconazole associated mucormycosis in a patient with relapsed acute lymphoblastic leukemia and hematopoietic stem cell transplant failure: A case report

Cited by 5 publications

References 24 publications

Focusing COVID-19-associated mucormycosis: a major threat to immunocompromised COVID-19

Focusing COVID-19-associated mucormycosis: a major threat to immunocompromised COVID-19

Cutaneous Mucormycosis of the Interscapular Region in an Immunocompetent Patient

Voriconazole

Contact Info

Product

Resources

About